Canine mammary tumours as a model to study human breast cancer: Most recent findings

In Vivo

Volumn 25, Issue 3, 2011, Pages 455-465

  Queiroga, Felisbina Luisa ^a   Raposo, Teresa ^b   Carvalho, Maria Isabel ^b   Prada, Justina ^a   Pires, Isabel ^a  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

Author keywords

Canine mammary tumours; Canine model; Dog; Human breast cancer; Mammary; Molecular markers; Prognosis; Review

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH HORMONE; HEAT SHOCK PROTEIN; MASPIN; METALLOPROTEINASE; MUCIN; PHOSPHATASE; PROGESTERONE RECEPTOR; PROLACTIN; PROSTAGLANDIN SYNTHASE; PROTEIN P53; PROTEIN P63; SIALYL LEWIS X ANTIGEN; SOMATOMEDIN C; STEROID RECEPTOR; TENSIN; TUMOR MARKER;

BREAST CANCER; BREAST TUMOR; CANCER INVASION; CANCER STAGING; DISEASE MODEL; DOG; GENE MUTATION; HISTOPATHOLOGY; NONHUMAN; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 79956347959     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. Strandberg JD and Goodman DG: Animal model of human disease: canine mammary neoplasia. Am J Pathol 75: 225-228, 1974.
2. Misdorp W and Hart AA: Prognostic factors in canine mammary cancer. J Natl Cancer Inst 56: 779-786, 1976.
3. Lilienfeld AM: The epidemiology of breast cancer. Cancer Res 23: 1503-1513, 1963.
4. Metzger FL: Senior and geriatric care programs for veterinarians. Vet Clin North Am Small Anim Pract 35: 743-753, 2005.
5. Bernstein L: Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 7: 3-15, 2002.
6. Donnay I, Rauis J, Devleeschouwer N, Wouters-Ballman P, Leclercq G and Verstegen J: Comparison of estrogen and progesterone receptor expression in normal and tumor mammary tissues from dogs. Am J Vet Res 56: 1188-1194, 1995.
7. Glass AG, Lacey JV Jr., Carreon JD and Hoover RN: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99: 1152-1161, 2007.
8. Pollan M, Pastor-Barriuso R, Ardanaz E, Arguelles M, Martos C, Galceran J, Sanchez-Perez MJ, Chirlaque MD, Larranaga N, Martinez-Cobo R, Tobalina MC, Vidal E, Marcos-Gragera R, Mateos A, Garau I, Rojas-Martin MD, Jimenez R, Torrella-Ramos A, Perucha J, Perez-de-Rada ME, Gonzalez S, Rabanaque MJ, Borras J, Navarro C, Hernandez E, Izquierdo A, Lopez-Abente G and Martinez C: Recent changes in breast cancer incidence in Spain, 1980-2004. J Natl Cancer Inst 101: 1584-1591, 2009.
9. Dobson JM, Samuel S, Milstein H, Rogers K and Wood JL: Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract 43: 240-246, 2002. (Pubitemid 135748518)
10. Schneider R: Comparison of age, sex, and incidence rates in human and canine breast cancer. Cancer 26: 419-426, 1970.
11. MacEwen EG, Patnaik AK, Harvey HJ and Panko WB: Estrogen receptors in canine mammary tumors. Cancer Res 42: 2255-2259, 1982. (Pubitemid 12121442)
12. Rutteman GR, Misdorp W, Blankenstein MA and van den Brom WE: Oestrogen (ER) and progestin receptors (PR) in mammary tissue of the female dog: different receptor profile in non-malignant and malignant states. Br J Cancer 58: 594-599, 1988. (Pubitemid 19010708)
13. Block GE, Jensen EV and Polley TZ: The prediction of hormonal dependency of mammary cancer. Ann Surg 182: 342-352, 1975.
14. Fisher ER, Sass R and Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project. Correlations with concordant and discordant estrogen and progesterone receptors. Cancer 59: 1554-1559, 1987.
15. Sonnenschein EG, Glickman LT, Goldschmidt MH and McKee LJ: Body conformation, diet, and risk of breast cancer in pet dogs: a case-control study. Am J Epidemiol 133: 694-703, 1991.
16. Perez Alenza D, Rutteman GR, Pena L, Beynen AC and Cuesta P: Relation between habitual diet and canine mammary tumors in a case control study. J Vet Intern Med 12: 132-139, 1998.
17. Greenberg ER, Vessey MP, McPherson K, Doll R and Yeates D: Body size and survival in premenopausal breast cancer. Br J Cancer 51: 691-697, 1985. (Pubitemid 15095750)
18. Kotsopoulos J, Olopado OI, Ghadirian P, Lubinski J, Lynch HT, Isaacs C, Weber B, Kim-Sing C, Ainsworth P, Foulkes WD, Eisen A, Sun P and Narod SA: Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 7: R833-843, 2005.
19. Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, Folsom AR and Sellers TA: Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 14: 656-661, 2005. (Pubitemid 40489211)
20. Akiyama F and Horii R: Therapeutic strategies for breast cancer based on histological type. Breast Cancer 16: 168-172, 2009.
21. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ and Peterse JL: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216: 141-150, 2008.
22. Misdorp W: Histological classification of mammary tumors of the dog and the cat. Washington: Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology, p. 59, 1999.
23. Elston CW: Classification and grading of invasive breast carcinoma. Verh Dtsch Ges Pathol 89: 35-44, 2005.
24. Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AH and Ellis IO: Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 111: 121-127, 2008. (Pubitemid 352009237)
25. Karayannopoulou M, Kaldrymidou E, Constantinidis TC and Dessiris A: Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. J Comp Pathol 133: 246-252, 2005. (Pubitemid 41671219)
26. Gilbertson SR, Kurzman ID, Zachrau RE, Hurvitz AI and Black MM: Canine mammary epithelial neoplasms: biologic implications of morphologic characteristics assessed in 232 dogs. Vet Pathol 20: 127-142, 1983. (Pubitemid 13087502)
27. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S and Contag CH: Animal models of bone metastasis. Cancer 97: 748-757, 2003. (Pubitemid 36125810)
28. Shek LL and Godolphin W: Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res 48: 5565-5569, 1988.
29. Stevanovic A, Lee P and Wilcken N: Metastatic breast cancer. Aust Fam Physician 35: 309-312, 2006.
30. Abner AL, Collins L, Peiro G, Recht A, Come S, Shulman LN, Silver B, Nixon A, Harris JR, Schnitt SJ and Connolly JL: Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer 83: 2502-2508, 1998. (Pubitemid 29019569)
31. Hellmen E, Bergstrom R, Holmberg L, Spangberg IB, Hansson K and Lindgren A: Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases. Vet Pathol 30: 20-27, 1993.
32. Sarli G, Preziosi R, Benazzi C, Castellani G and Marcato PS: Prognostic value of histologic stage and proliferative activity in canine malignant mammary tumors. J Vet Diagn Invest 14: 25-34, 2002.
33. Lamote I, Meyer E, Massart-Leen AM and Burvenich C: Sex steroids and growth factors in the regulation of mammary gland proliferation, differentiation, and involution. Steroids 69: 145-159, 2004.
34. Knight WA, Livingston RB, Gregory EJ and McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37: 4669-4671, 1977. (Pubitemid 8239679)
35. Balfe P, McCann A, McGoldrick A, McAllister K, Kennedy M, Dervan P and Kerin MJ: Estrogen receptor alpha and beta profiling in human breast cancer. Eur J Surg Oncol 30: 469-474, 2004.
36. Martin de las Mulas J, Ordas J, Millan MY, Chacon F, De Lara M, Espinosa de los Monteras A, Reymundo C and Jover A: Immunohistochemical expression of estrogen receptor beta in normal and tumoral canine mammary glands. Vet Pathol 41: 269-272, 2004.
37. Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, Peterson C, Malmstrom P, Isola J, Borg A and Ferno M: Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 13: 1987-1994, 2007.
38. Saji S, Hirose M and Toi M: Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol 56 Suppl 1: 21-26, 2005.
39. Anderson E: The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 4: 197-201, 2002.
40. Gelbfish GA, Davidson AL, Kopel S, Schreibman B, Gelbfish JS, Degenshein GA, Herz BL and Cunningham JN: Relationship of estrogen and progesterone receptors to prognosis in breast cancer. Ann Surg 207: 75-79, 1988. (Pubitemid 18057276)
41. Chevallier B, Mosseri V, Dauce JP, Bastit P, Julien JP and Asselain B: A prognostic score in histological node-negative breast cancer. Br J Cancer 61: 436-440, 1990. (Pubitemid 20106022)
42. Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S, Rallet A, Courriere P, Millon R and Asselain B: Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 73: 1545-1551, 1996. (Pubitemid 26235381)
43. Krajcik RA, Borofsky ND, Massardo S and Orentreich N: Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 11: 1566-1573, 2002.
44. Kleinberg DL, Wood TL, Furth PA and Lee AV: Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 30: 51-74, 2009.
45. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN and Hankinson SE: Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13: 583-592, 2006. (Pubitemid 43886678)
46. Selman PJ, Mol JA, Rutteman GR, van Garderen E and Rijnberk A: Progestin-induced growth hormone excess in the dog originates in the mammary gland. Endocrinology 134: 287-292, 1994.
47. van Garderen E, de Wit M, Voorhout WF, Rutteman GR, Mol JA, Nederbragt H and Misdorp W: Expression of growth hormone in canine mammary tissue and mammary tumors. Evidence for a potential autocrine/paracrine stimulatory loop. Am J Pathol 150: 1037-1047, 1997. (Pubitemid 27106174)
48. van Garderen E, van der Poel HJ, Swennenhuis JF, Wissink EH, Rutteman GR, Hellmen E, Mol JA and Schalken JA: Expression and molecular characterization of the growth hormone receptor in canine mammary tissue and mammary tumors. Endocrinology 140: 5907-5914, 1999. (Pubitemid 30645380)
49. Queiroga FL, Perez-Alenza MD, Silvan G, Pena L, Lopes CS and Illera JC: Crosstalk between GH/IGF-I axis and steroid hormones (progesterone, 17beta-estradiol) in canine mammary tumours. J Steroid Biochem Mol Biol 110: 76-82, 2008.
50. Queiroga FL, Perez-Alenza MD, Silvan G, Pena L, Lopes C and Illera JC: Role of steroid hormones and prolactin in canine mammary cancer. J Steroid Biochem Mol Biol 94: 181-187, 2005. (Pubitemid 40626715)
51. Queiroga FL, Perez-Alenza D, Silvan G, Pena L, Lopes CS and Illera JC: Serum and intratumoural GH and IGF-I concentrations: Prognostic factors in the outcome of canine mammary cancer. Res Vet Sci 89: 396-403, 2010.
52. Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK and Lee AV: The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 98: 315-327, 2006. (Pubitemid 44195602)
53. Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA and Sharma A: Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 13: 1000-1009, 2007. (Pubitemid 46340379)
54. Hobbs JR and Salih H: Prolactin dependence in human breast cancer. Proc R Soc Med 66: 866, 1973.
55. Ormandy CJ, Hall RE, Manning DL, Robertson JF, Blarney RW, Kelly PA, Nicholson RI and Sutherland RL: Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab 82: 3692-3699, 1997. (Pubitemid 27509357)
56. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984. (Pubitemid 14035254)
57. Crispino S, Brenna A, Colombo D, Flores B, D'Amico S, Lissoni P, Barni S, Paolorossi F, Bratina G and Tancini G: Ki-67 labeling index in breast cancer. Tumori 75: 557-562, 1989.
58. Menezes HL, Juca MJ, Gomes EG, Nunes BL, Costa HO and Matos D: Analysis of the immunohistochemical expressions of p53, BCL-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors. Arq Gastroenterol 47: 141-147, 2010.
59. Vacchi-Suzzi M, Bocciolini C, Bertarelli C and Dall'Olio D: Ki-67 proliferation rate as a prognostic marker in major salivary gland carcinomas. Ann Otol Rhinol Laryngol 119: 677-683, 2010.
60. Buishand FO, Kik M and Kirpensteijn J: Evaluation of clinicopathological criteria and the Ki-67 index as prognostic indicators in canine insulinoma. Vet J 185: 62-67, 2010.
61. Pena LL, Nieto AI, Perez-Alenza D, Cuesta P and Castano M: Immunohistochemical detection of Ki-67 and Pcna in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest 10: 237-246, 1998. (Pubitemid 128657080)
62. kip1 in canine pituitary corticotroph adenomas. Dornest Anim Endocrinol 38: 244-252, 2010.
63. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L and von Smitten K: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 68: 579-583, 1993. (Pubitemid 23258465)
64. Keshgegian AA and Cnaan A: Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 104: 42-49, 1995.
65. Haerslev T, Jacobsen GK and Zedeler K: Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 37: 101-113, 1996. (Pubitemid 26030089)
66. Biesterfeld S, Kluppel D, Koch R, Schneider S, Steinhagen G, Mihalcea AM and Schroder W: Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR. J Pathol 185: 25-31, 1998. (Pubitemid 28266713)
67. Bukholm IR, Bukholm G, Holm R and Nesland JM: Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas. J Clin Pathol 56: 368-373, 2003. (Pubitemid 36566823)
68. Sheen-Chen SM, Eng HL, Chou FF and Chen WJ: The prognostic significance of proliferating cell nuclear antigen in patients with lymph node-positive breast cancer. Arch Surg 132: 264-267, 1997.
69. Schonborn I, Zschiesche W, Minguillon C, Spitzer E, Mohner M, Ebeling K and Grosse R: Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer. J Cancer Res Clin Oncol 121: 115-122, 1995.
70. Kato T, Kimura T, Miyakawa R, Fujii A, Yamamoto K, Kameoka S, Nishikawa T and Kasajima T: Clinicopathologic study associated with long-term survival in Japanese patients with node-negative breast cancer. Br J Cancer 82: 404-411, 2000. (Pubitemid 30045389)
71. Thomas M, Noguchi M, Kitagawa H, Kinoshita K and Miyazaki I: Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma. J Clin Pathol 46: 525-528, 1993. (Pubitemid 23209848)
72. Funakoshi Y, Nakayama H, Uetsuka K, Nishimura R, Sasaki N and Doi K: Cellular proliferative and telomerase activity in canine mammary gland tumors. Vet Pathol 37: 177-183, 2000.
73. Kumaraguruparan R, Prathiba D and Nagini S: Of humans and canines: Immunohistochemical analysis of PCNA, BCL-2, p53, cytokeratin and ER in mammary tumours. Res Vet Sci 81: 218-224, 2006.
74. Velculescu VE and El-Deiry WS: Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 42: 858-868, 1996.
75. Kim K, Chie EK, Han W, Noh DY, Park IA, Oh DY, Im SA, Kim TY, Bang YJ and Ha SW: Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy. J Korean Med Sci 25: 235-239, 2010.
76. Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, Krontiras H, Urist MM and Bland KI: Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg 233: 630-638, 2001. (Pubitemid 32378646)
77. Lee CH, Kim WH, Lim JH, Kang MS, Kim DY and Kweon OK: Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. J Vet Sci 5: 63-69, 2004.
78. Lee CH and Kweon OK: Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors. J Vet Sci 3: 321-325, 2002.
79. Wakui S, Muto T, Yokoo K, Yokoo R, Takahashi H, Masaoka T, Hano H and Furusato M: Prognostic status of p53 gene mutation in canine mammary carcinoma. Anticancer Res 21: 611-616, 2001. (Pubitemid 32267581)
80. Chu LL, Rutteman GR, Kong JM, Ghahremani M, Schmeing M, Misdorp W, van Garderen E and Pelletier J: Genomic organization of the canine p53 gene and its mutational status in canine mammary neoplasia. Breast Cancer Res Treat 50: 11-25, 1998. (Pubitemid 28438857)
81. Muto T, Wakui S, Takahashi H, Maekawa S, Masaoka T, Ushigome S and Furusato M: p53 gene mutations occurring in spontaneous benign and malignant mammary tumors of the dog. Vet Pathol 37: 248-253, 2000.
82. Veldhoen N, Watterson J, Brash M and Milner J: Identification of tumour-associated and germ-line p53 mutations in canine mammary cancer. Br J Cancer 81: 409-415, 1999. (Pubitemid 29458793)
83. Moll UM and Slade N: p63 and p73: roles in development and tumor formation. Mol Cancer Res 2: 371-386, 2004. (Pubitemid 39031071)
84. McKeon FD: p63 and p73 in tumor suppression and promotion. Cancer Res Treat 36: 6-12, 2004.
85. Matos I, Dufloth R, Alvarenga M, Zeferino LC and Schmitt F: p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447: 688-694, 2005. (Pubitemid 41571183)
86. Stefanou D, Batistatou A, Nonni A, Arkoumani E and Agnantis NJ: p63 expression in benign and malignant breast lesions. Histol Histopathol 19: 465-471, 2004. (Pubitemid 38450633)
87. Gama A, Alves A, Gartner F and Schmitt F: p63: a novel myoepithelial cell marker in canine mammary tissues. Vet Pathol 40: 412-420, 2003. (Pubitemid 38410623)
88. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L and Bloom KJ: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8: 307-325, 2003.
89. Rungsipipat A, Tateyama S, Yamaguchi R, Uchida K, Miyoshi N and Hayashi T: Immunohistochemical analysis of c-Yes and c-ErbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. J Vet Med Sci 61: 27-32, 1999. (Pubitemid 129581158)
90. Kerns BJ, Pence JC, Huper G, Kinney RB and Iglehart JD: c-erbB-2 expression in breast cancer detected by immunoblotting and immunohistochemistry. J Histochem Cytochem 38: 1823-1830, 1990.
91. Paredes J, Lopes N, Milanezi F and Schmitt FC: P-Cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch 450: 73-80, 2007. (Pubitemid 46360747)
92. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blarney RW, Robertson JF, Nicholson RI and Ellis IO: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203: 661-671, 2004. (Pubitemid 38714103)
93. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL and Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.
94. Gama A, Alves A and Schmitt F: Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch 453: 123-132, 2008.
95. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32, 2007. (Pubitemid 46120191)
96. Gama A, Gartner F, Alves A and Schmitt F: Immunohistochemical expression of epidermal growth factor receptor (Egfr) in canine mammary tissues. Res Vet Sci 87: 432-437, 2009.
97. Queiroga FL, Perez-Alenza D, Silvan G, Pena L and Illera JC: Positive correlation of steroid hormones and Egf in canine mammary cancer. J Steroid Biochem Mol Biol 115: 9-13, 2009.
98. Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR and West SC: Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7: 273-282, 2001. (Pubitemid 32206495)
99. Soderlund K, Skoog L, Fornander T and Askmalm MS: The BRCA1/BRCA2/RAD51 complex is a prognostic and predictive factor in early breast cancer. Radiother Oncol 84: 242-251, 2007. (Pubitemid 47371156)
100. Klopfleisch R and Gruber AD: Increased expression of Brca2 and Rad51 in lymph node metastases of canine mammary adenocarcinomas. Vet Pathol 46: 416-422, 2009.
101. Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J, Palombo F, Viti V, Mesiti G, Zappulli V, Marconato L, Abramo F, Ciliberto G, Lahm A, La Monica N and de Rinaldis E: Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics 10: 135, 2009.
102. Woodhouse EC, Chuaqui RF and Liotta LA: General mechanisms of metastasis. Cancer 80: 1529-1537, 1997.
103. Shah FD, Shukla SN, Shah PM, Shukla HK and Patel PS: Clinical significance of matrix metalloproteinase-2 and -9 in breast cancer. Indian J Cancer 46: 194-202, 2009.
104. Hirayama K, Yokota H, Onai R, Kobayashi T, Kumata T, Kihara K, Okamoto M, Sako T, Nakade T, Izumisawa Y and Taniyama H: Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography. J Comp Pathol 127: 249-256, 2002. (Pubitemid 35373407)
105. Loukopoulos P, Mungall BA, Straw RC, Thornton JR and Robinson WF: Matrix metalloproteinase-2 and -9 involvement in canine tumors. Vet Pathol 40: 382-394, 2003. (Pubitemid 38406131)
106. Tamguney T and Stokoe D: New insights into PTEN. J Cell Sci 120: 4071-4079, 2007.
107. Depowski PL, Rosenthal SI and Ross JS: Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14: 672-676, 2001. (Pubitemid 32667211)
108. Ressel L, Millanta F, Caleri E, Innocenti VM and Poli A: Reduced Pten protein expression and its prognostic implications in canine and feline mammary tumors. Vet Pathol 46: 860-868, 2009.
109. Qiu CW, Lin DG, Wang JQ, Li CY and Deng GZ: Expression and significance of Pten and Vegf in canine mammary gland tumours. Vet Res Commun 32: 463-472, 2008.
110. Calabrese V, Cornelius C, Dinkova-Kostova AT and Calabrese EJ: Vitagenes, cellular stress response, and acetylcarnitine: relevance to hormesis. Biofactors 35: 146-160, 2009.
111. Schmitt E, Gehrmann M, Brunet M, Multhoff G and Garrido C: Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 81: 15-27, 2007. (Pubitemid 46021247)
112. Kumaraguruparan R, Karunagaran D, Balachandran C, Manohar BM and Nagini S: Of humans and canines: a comparative evaluation of heat-shock and apoptosis-associated proteins in mammary tumors. Clin Chim Acta 365: 168-176, 2006. (Pubitemid 43196434)
113. Kufe DW: Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 9: 874-885, 2009.
114. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF and Ellis IO: Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 18: 1295-1304, 2005. (Pubitemid 41348648)
115. Chu JS and Chang KJ: Mucin expression in mucinous carcinoma and other invasive carcinomas of the breast. Cancer Lett 142: 121-127, 1999.
116. de Oliveira JT, Pinho SS, de Matos AJ, Hespanhol V, Reis CA and Gartner F: Muc1 expression in canine malignant mammary tumours and relationship to clinicopathological features. Vet J 182: 491-493, 2009.
117. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ and Sager R: Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA 93: 11669-11674, 1996. (Pubitemid 26347180)
118. Lee MJ, Suh CH and Li ZH: Clinicopathological significance of maspin expression in breast cancer. J Korean Med Sci 21: 309-314, 2006.
119. Espinosa de los Monteros A, Millan MY, Ramirez GA, Ordas J, Reymundo C and Martin de las Mulas J: Expression of maspin in mammary gland tumors of the dog. Vet Pathol 42: 250-257, 2005.
120. Ugorski M and Laskowska A: Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim Pol 49: 303-311, 2002.
121. Renkonen J, Paavonen T and Renkonen R: Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int J Cancer 74: 296-300, 1997. (Pubitemid 27321799)
122. Sozzani P, Arisio R, Porpiglia M and Benedetto C: Is sialyl Lewis x antigen expression a prognostic factor in patients with breast cancer?. Int J Surg Pathol 16: 365-374, 2008.
123. Nakagawa T, Uyama R, Ohashi E, Takahashi T, Hong SH, Mochizuki M, Matsunaga S, Nishimura R and Sasaki N: The expression of sialyl Lewis X in canine and feline mammary gland tumors. J Vet Med Sci 64: 949-952, 2002.
124. Pinho SS, Matos AJ, Lopes C, Marcos NT, Carvalheira J, Reis CA and Gartner F: Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-cadherin expression. BMC Cancer 7: 124, 2007.
125. Prescott SM and Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470: M69-78, 2000.
126. Hwang D, Scollard D, Byrne J and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90: 455-460, 1998. (Pubitemid 28160637)
127. Dore M, Lanthier I and Sirois J: Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol 40: 207-212, 2003. (Pubitemid 38393599)
128. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J and Koki AT: COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89: 2637-2645, 2000.
129. Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, Kristiansen G, Reles A, Siegert A, Guski H and Hauptmann S: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease-free survival and overall survival in patients with breast carcinoma. Cancer 97: 2978-2987, 2003. (Pubitemid 36676251)
130. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H and Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635, 2002. (Pubitemid 34126931)
131. Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A, Margreiter R and Obrist P: Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 88: 574-578, 2003. (Pubitemid 36363367)
132. Boland GP, Butt IS, Prasad R, Knox WF and Bundred NJ: COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90: 423-429, 2004. (Pubitemid 38250640)
133. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I and Schmitt FC: Cyclooxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55: 429-434, 2002. (Pubitemid 34620779)
134. Queiroga FL, Perez-Alenza MD, Silvan G, Pena L, Lopes C and Illera JC: Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance. Anticancer Res 25: 4269-4275, 2005. (Pubitemid 41665215)
135. Dias Pereira P, Lopes CC, Matos AJ, Santos M, Gartner F, Medeiros R and Lopes C: Cox-2 expression in canine normal and neoplastic mammary gland. J Comp Pathol 140: 247-253, 2009.
136. Queiroga FL, Alves A, Pires I and Lopes C: Expression of Cox-1 and Cox-2 in canine mammary tumours. J Comp Pathol 136: 177-185, 2007. (Pubitemid 46546139)
137. Heller DA, Clifford CA, Goldschmidt MH, Holt DE, Shofer FS, Smith A and Sorenmo KU: Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma. Vet Pathol 42: 776-780, 2005. (Pubitemid 41695360)
138. Queiroga FL, Pires I, Lobo L and Lopes CS: The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours. Res Vet Sci 88: 441-445, 2010.
139. Davies G, Salter J, Hills M, Martin LA, Sacks N and Dowsett M: Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 9: 2651-2656, 2003.
140. Queiroga FL, Pires I, Parente M, Gregorio H and Lopes CS: Cox-2 overexpression correlates with Vegf and tumour angiogenesis in canine mammary cancer. Vet J, 2010. doi:10.1016/j.tvjl.2010.06.022. Jul 30, 2010.
141. Vermeulen PB, van Golen KL and Dirix LY: Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer 116: 2748-2754, 2010.